5139-19-5

Basic information

• Product Name: 2,3,4,5-tetra-O-acetyl-L-arabinose
• Synonyms: 2,3,4,5-tetra-O-acetyl-L-arabinose
• CAS NO: 5139-19-5
• Molecular Weight: 318.281
• Mol File: 5139-19-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,3,4,5-tetra-O-acetyl-L-arabinose(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-tetra-O-acetyl-L-arabinose(5139-19-5)
• EPA Substance Registry System: 2,3,4,5-tetra-O-acetyl-L-arabinose(5139-19-5)

Safety Data

• Hazardous Substances Data: 5139-19-5(Hazardous Substances Data)

Upstream product

• 7226-49-5 2,3,4,5-tetra-O-acetyl-D-xylose diethyl dithioacetal 
• 108-24-7 acetic anhydride 
• 59-23-4 D-Galactose 
• 58-86-6 D-xylose 

Downstream Products

• 7208-41-5 penta-O-acetyl-6-deoxy-L-glucitol 
• 7208-41-5 penta-O-acetyl-1-deoxy-D-iditol 
• 5151-92-8 2,3,4,5-tetra-O-acetyl-L-arabinose benzoylhydrazone 
• 86334-50-1 1-deoxy-D-gulitol 
• 3615-56-3 D-Sorbose 
• 57-48-7 L-fructose 
• 261176-74-3 O-(2,3,4-tri-O-acetyl-α-L-arabinosyl)trichloroacetimidate 
• 91-09-8 methyl β-L-arabinopyranoside 
• 38088-60-7 methyl 3,4-O-isopropylidene-β-L-arabinopyranoside 
• 120192-08-7 2,3,4,5-Tetra-O-acetyl-L-arabinose-N-methyl-N-(4-phenyl-thiazol-2-yl)hydrazon 
• 6632-52-6 tetra-O-acetyl-keto-1-deoxy-L-fructose 

Relevant articles and documents

Indiosides G-K: Steroidal glycosides with cytotoxic and anti-inflammatory activities from Solanum violaceum

Five new steroidal glycosides (1-5) and nine known compounds were isolated from Solanum violaceum. Indiosides G (1) and H (2) are spirostene saponins with an iso-type F ring, indioside I (3) is a spirostane saponin, and indiosides J (4) and K (5) are unusual furostanol saponins with a deformed F ring. These structures represent rare naturally occurring steroidal skeletons. The structures of the new compounds were elucidated using 1D and 2D spectroscopic techniques and acid hydrolysis. Compounds 2, 3, and 7-9 exhibited cytotoxic activity against six human cancer cell lines (HepG2, Hep3B, A549, Ca9-22, MDA-MB-231, and MCF-7) with IC50 values of 1.83-8.04 μg/mL. Steroidal saponins 3, 8, and 9 showed inhibitory effects on superoxide anion generation with IC50 values of 2.84 ± 0.18, 0.62 ± 0.03, and 1.62 ± 0.59 μg/mL, respectively. Saponins 8 and 9 also inhibited elastase release with IC50 values of 111.05 ± 7.37 and 4.04 ± 0.51 μg/mL, respectively. Structure-activity relationship correlations of these compounds with respect to cytotoxic and anti-inflammatory effects are discussed.

C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE

The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide and N-glycoside analogue of retinoyl beta-glucuronide that resist both beta-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)phenyl-C-xyloside, 1-(B-D-lucopyranosyl) retinamide and 1-(D-glucopyranosyluronosly) retinamide. The invention also relates to a method for making such drugs.